BIBW2992
Tovok,BIBW 2992
CAS: 439081-18-2;850140-72-6
Molecular Formula: C24H25ClFN5O3
BIBW2992 - Names and Identifiers
| Name | Tovok,BIBW 2992 |
| Synonyms | Tovok Afatinb AFATINIB BIBW2992 Afatinib BIBW 2992 BIBW2992 BIBW-2992 BIBW-2292 Afatinib(W.S) Tovok,BIBW 2992 Afatinib(cis-trans isomerismtautomers) (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dim (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl}-4-(dimethylamino)but-2-enamide (E)-N-(7-((S)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)- |
| CAS | 439081-18-2 850140-72-6 |
| EINECS | 1308068-626-2 |
| InChI | InChI=1/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+ |
BIBW2992 - Physico-chemical Properties
| Molecular Formula | C24H25ClFN5O3 |
| Molar Mass | 485.94 |
| Density | 1.380 |
| Boling Point | 676.9±55.0 °C(Predicted) |
| Flash Point | 363.186°C |
| Vapor Presure | 0mmHg at 25°C |
| pKa | 12.06±0.43(Predicted) |
| Storage Condition | -20 ° C, dark |
| Refractive Index | 1.668 |
| In vitro study | BIBW2992 irreversibly inhibits EGFR/HER2, and its IC50 is 0.5, 0.4, 10, and 14 nM when it acts on wild-type EGFR, L858R mutant EGFR, L858R/T790M double mutant EGFR, and HER2 in vitro, respectively. In the in vitro experiment, BIBW2992 showed strong vitality whether acting on wild-type EGFR/HER2 or mutant EGFR/HER2, which was similar to that of gefitinib acting on L858R mutant EGFR, however, it is 100 times more active than gefitinib in the L858R-T790M double mutant EGFR. In Vitro, BIBW2992 potently inhibited EGFR/HER phosphorylation in all cell types tested. Such as wild-type EGFR expressed by human flat epithelial carcinoma A431 cell line, wild-type HER2 transfected by murine NIH-3T3 cells, and endogenous HER2 expressed by breast cancer BT-474 cell lines and gastric cancer NCI-N87 cell lines. |
| In vivo study | In vivo study, according to the body weight of the experimental subjects, 20 mg BIBW2992 per kilogram was taken orally for 25 days, and the tumor produced obvious recession phenomenon, which was observed by immunohistochemical staining of tumor sections, the phosphorylation of EGFR and AKT was inhibited. Thus, like lapatinib and neratinib, BIBW2992 is a secondary tyrosine kinase inhibitor that irreversibly inhibits human EGFR2(HER2) and EGFR kinases. BIBW2992 is not only as effective as primary tyrosine kinases such as erlotinib and gefitinib in inhibiting EGFR mutants, but also acts on EGFR resistant to erlotinib and gefinib. |
BIBW2992 - Risk and Safety
| HS Code | 29349990 |
Supplier List
Multiple SpecificationsSpot supply
Product Name: Afatinib Visit Supplier Webpage Request for quotationCAS: 850140-72-6
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: Afatinib Visit Supplier Webpage Request for quotationCAS: 850140-72-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Afatinib Visit Supplier Webpage Request for quotationCAS: 850140-72-6
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: Afatinib Visit Supplier Webpage Request for quotationCAS: 850140-72-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History